Pfizer Inc (PFIZ34) — Cash Flow Quality Index
Latest as of March 2026:
0.97x
Pfizer Inc (PFIZ34) has a Cash Flow Quality Index of 0.97x as of March 2026. Operating cash flow of R$2.62 Billion is below net income of R$2.69 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore PFIZ34 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
0.97x
Operating CF / Net Income
Operating Cash Flow
R$2.62 Billion
BRL
Net Income
R$2.69 Billion
BRL
Data as of
Mar 2026
Most recent filing
Pfizer Inc Cash Flow Quality Index (2014–2025)
Historical Cash Flow Quality Index for Pfizer Inc across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of Pfizer Inc.
Annual Cash Flow Quality Index for Pfizer Inc (2014–2025)
Year-by-year earnings quality comparison for Pfizer Inc.
| Year | Quality Index | Operating CF (BRL) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.50x | R$11.71 Billion | R$7.81 Billion | ▼ -5.6% |
| 2024 | 1.59x | R$12.74 Billion | R$8.03 Billion | ▼ -72.1% |
| 2023 | 5.68x | R$12.04 Billion | R$2.12 Billion | ▲ +509.2% |
| 2022 | 0.93x | R$29.27 Billion | R$31.37 Billion | ▼ -37.1% |
| 2021 | 1.48x | R$32.58 Billion | R$21.98 Billion | ▼ -0.7% |
| 2020 | 1.49x | R$14.40 Billion | R$9.65 Billion | ▲ +93.3% |
| 2019 | 0.77x | R$12.59 Billion | R$16.30 Billion | ▼ -45.4% |
| 2018 | 1.41x | R$15.83 Billion | R$11.19 Billion | ▲ +79.8% |
| 2017 | 0.79x | R$16.80 Billion | R$21.36 Billion | ▼ -64.8% |
| 2016 | 2.23x | R$16.19 Billion | R$7.25 Billion | ▲ +5.9% |
| 2015 | 2.11x | R$14.69 Billion | R$6.96 Billion | ▲ +12.8% |
| 2014 | 1.87x | R$17.08 Billion | R$9.13 Billion | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.